Andrew Haupt

Partner

Andrew Haupt advises pharmaceutical, biotechnology, and other life sciences companies on complex strategic transactions, with a particular focus on licensing and collaboration agreements, external innovation and partnering arrangements, option and asset acquisition structures, and co-development and co-commercialization arrangements. His clients include pharmaceutical, biotech, vaccine, medical device, technology, and emerging growth companies as well as private equity firms. Prior to private practice, Andrew was corporate counsel to a publicly traded biopharmaceutical company.

  • Bristol Myers Squibb in its multi-program global strategic collaboration and license agreements with Hengrui Pharma to advance innovative medicines across oncology, hematology and immunology, including a $600 million upfront payment, up to $350 million in anniversary payments, and up to $15.2 billion in total potential value
  • Prelude Therapeutics in its strategic agreement with Incyte Corporation valued up to $910 million that includes an exclusive option agreement with Incyte to advance its mutant selective JAK2V617F JH2 inhibitor program for patients with myeloproliferative neoplasms
  • Bristol Myers Squibb in its global strategic partnership agreement with BioNTech SE to co-develop and co-commercialize BNT327, a next-generation antibody targeting PD-L1 and VEGF for the treatment of multiple solid tumor types, and valued up to $11.1 billion
  • Elektrofi Inc., a biopharmaceutical formulation technology company, in its sale to Halozyme Therapeutics Inc., comprised of an upfront payment of $750 million and up to three $50 million milestone payments contingent on three separate product regulatory approvals
  • Bristol Myers Squibb in its agreement with Bain Capital to create a new independent biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launched with five immunology assets in-licensed from Bristol Myers Squibb and a $300 million financing commitment that was led by Bain Capital
  • Bristol Myers Squibb in its global exclusive license agreement valued up to $1.35 billion with BioArctic AB for BioArctic's PyroGlutamate-amyloid-beta antibody program for Alzheimer’s disease
  • Bristol Myers Squibb in its collaboration and investment agreement valued up to $2.3 billion with Avidity Biosciences, Inc., to discover, develop and commercialize up to five cardiovascular targets leveraging Avidity's proprietary AOC platform technology
  • Bristol Myers Squibb in its exclusive license agreement valued up to $905 million with BridgeBio Pharma, Inc. to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology
  • Bristol Myers Squibb in its license, development and commercialization agreement valued up to $920 million with Immatics N.V. for Immatics’ T cell-redirecting cancer immunotherapy candidate, IMA401
  • Idera Pharmaceuticals, Inc. in the acquisition of Aceragen, Inc., a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments
  • Regeneron in its license and collaboration agreement with Nykode Therapeutics for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases
  • Bristol Myers Squibb in its up to $3.1 billion global strategic collaboration with Eisai Co., Ltd. for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC) combining an anti-folate receptor alpha (FRα) antibody and anticancer agent eribulin
  • Healthcare Royalty Partners in a royalty monetization transaction with REGENXBIO Inc.
  • Oncoceutics, Inc., a clinical-stage biotechnology company developing imipridones, a novel class of compounds, in its sale up to $450 million to Chimerix
  • Takeda in its license and collaboration arrangement with Novavax for production and commercialization of Novavax’s COVID-19 vaccine candidate in Japan
  • Takeda in the sale to Neuraxpharm of global rights to the prescription brand Buccolam® (indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures)
  • Astellas in its acquisition of Xyphos Biosciences, a development-stage biotechnology company focused on immuno-oncology therapeutics, for a total transaction value of up to USD $665 million including USD $120 million upfront and potential future development milestone payments
  • AbbVie in the exclusive option and license agreement with Harpoon for HPN217, Harpoon's BCMA-targeting Tri-specific T cell Activating Construct
  • AbbVie in its exclusive license agreement with Disc Medicine granting worldwide rights to a series of hemojuvelin antagonist monoclonal antibodies
  • H. Lundbeck A/S in its acquisition via tender offer of Alder BioPharmaceuticals, in a transaction valued at approximately $1.95 billion, consisting of cash and contingent value rights (CVRs)
  • H. Lundbeck A/S in its acquisition of Abide Therapeutics, a clinical-stage biopharmaceutical company focusing on multiple indications in neurology and psychiatry, for $250 million upfront and up to an additional $150 million in development and sales milestones
  • Regeneron in its up to $1 billion agreement with Alnylam Pharmaceuticals for the development and commercialization of new RNA interference therapeutics for diseases in the eye, central nervous system and liver. As part of the transaction, Regeneron made a $400 million investment in Alnylam equity
  • AbbVie in a collaboration and option agreement with Mission Therapeutics to research and develop specified DUB inhibitors for the treatment of Alzheimer's Disease and Parkinson's Disease
  • Merck KGaA in its novel risk-sharing collaboration agreement with SFJ Pharmaceuticals for development of Merck’s abituzumab as a first-line treatment for metastatic colorectal cancer in combination with Erbitux® and chemotherapy
  • A pharmaceutical company in a collaboration and option agreement with a data-driven design company to apply AI to the discovery, research and development of clinical candidates for the treatment of disorders in the central nervous system
  • A biopharmaceutical company in a $23 million preferred stock financing with various investors and a license and supply agreement with a pharmaceutical company to develop and commercialize a drug device combination product for the treatment of epileptic seizures
  • Multiple clients in license, research, option, service, and other agreements with various universities including the University of Pennsylvania, Yale University, Vanderbilt University, Drexel University, the University of Massachusetts, and the University of Texas
  • University of Chicago Law School, 2011, J.D.
  • Davidson College, 2005, A.B., Philosophy, minor in Mathematics, cum laude, Phi Beta Kappa
  • Pennsylvania

Recommended, Intellectual property, Patents: licensing, The Legal 500 US (2026)

Listed, The Best Lawyers in America, Ones to Watch, Healthcare Law, Philadelphia (2024, 2025)

Listed, The Best Lawyers in America, Ones to Watch, Mergers and Acquisitions Law, Philadelphia (2024, 2025)